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52The Vitiligo Impact Patient Scale (VIPs):
Development and Validation of a Vitiligo
Burden Assessment Tool
Camille Salzes1, Sophie Abadie2, Julien Seneschal1,3, Maxine Whitton4, Jean-Marie Meurant5,
Thomas Jouary6, Fabienne Ballanger1, Franck Boralevi1, Alain Taieb1,3, Charles Taieb7 and
Khaled Ezzedine1,3Vitiligo has a major impact on health-related quality of life. Although a few vitiligo-specific quality of life in-
struments exist, there is no specific vitiligo burden tool. We developed and validated a specific vitiligo burden
tool according to skin phototype. In total, 301 patients completed 35 items of the Vitiligo Impact Patient scale, of
whom 235 were of skin phototype I to III and 66 of phototype IV to VI. The dimensionality of the items was
evaluated using factor analyses, with results suggesting three factors in fair- and dark-skinned patients (“Psy-
chological effects on daily life,” “Relationships and Sexuality,” and “Economic Constraints, Care &Management
of Disease”). Unidimensionality was confirmed by higher order factor analysis. Cronbach’s a were high—and
intradimensional coherences all demonstrated good reliability (a > 0.8). The final instrument consists of 29
items (19 items common to all patients, 3 specific to fair skin, and 7 to dark skin). The test-retest reliability
demonstrated very good reproducibility. The intraclass correlation of each dimension was greater than 0.90 for
each population. External validity was confirmed by the correlation coefficients and Bland and Altman plots of
the Vitiligo Impact Patient scale-Fair Skin and Vitiligo Impact Patient scale-Dark Skin versus the Short-Form-12,
PVC Metra, Body Image States Scale, and Daily Life Quality Index assessment tools.
Journal of Investigative Dermatology (2016) 136, 52-58; doi:10.1038/JID.2015.398INTRODUCTION
Vitiligo is the most common depigmenting disorder, with a
prevalence of approximately 1% in the world population
(Ezzedine et al., 2015). In some countries, vitiligo is still
confused with leprosy with a considerable social stigma, and
in India, vitiligo has been referred to as “Sweta Kustha,”
which means “white leprosy” (Parsad et al., 2003a). Despite
this negative perception by the general population, and even
though it is classified by the WHO as a disease (L80), vitiligo
is often considered as a benign disorder and most derma-
tologists do not offer active treatment, being pessimistic
about the effect of therapeutic interventions on physical
symptoms (Ongenae et al., 2004) whilst ignoring the effect of
therapeutic interventions on the psychological and social
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Journal of Investigative Dermatology (2016), Volume 136 ª 2015 The Astudies have documented significant effects of vitiligo on
health-related quality of life (QoL), using validated generic
and dermatology-specific health-related QoL scales (Firooz
et al., 2004; Kent and Al’Abadie, 1996; Kent and al-
Abadie, 1996; Kostopoulou et al., 2009; Mattoo et al.,
2002; Parsad et al., 2003a; Porter et al., 1978, 1986, 1990;
Radtke et al., 2009; Sampogna et al., 2008; Schmid-Ott et al.,
2007; Talsania et al., 2010). However, these generic in-
struments are not specifically designed for vitiligo and are
probably not sensitive enough to detect subtle and relevant
variations of QoL between individuals. Recently, a few spe-
cific vitiligo QoL questionnaires have been developed (Gupta
et al., 2014; Lilly et al., 2013; Senol et al., 2013).
The concept of “burden” has played an increasingly
important role in evaluating the care of chronic diseases, and
more specifically skin diseases (Chren and Weinstock, 2004).
The notion of global burden was introduced by the WHO and
is useful in quantifying the health of a population and deter-
mining priorities of action in the public health domain (WHO,
2010). The notion of burden has recently been extended to
individuals and their families, to assess disability in a broad
sense (psychological, social, economic, and physical), related
to various diseases including psoriasis (Meyer et al., 2010),
infantile hemangioma (Boccara et al., 2015), inherited ich-
thyosis (Dufresne et al., 2013), and atopic dermatitis
(Taieb et al., 2015). Indeed, in a recent paper, Hay et al. (2014)
estimated the global burden of 15 skin diseases in 187
countries. This global burden takes into account not only
health-related QoL but also social integration, emotional
state, everyday-life organization, and the use of medical re-
sources including consultations and medication.uthors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
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The Vitiligo Impact Patient ScaleTo the best of our knowledge, there is no tool available for
assessing the burden experienced by individuals affected by
vitiligo, although there is a need for developing such a tool
that would be beneficial for clinicians and patients alike and
which would also allow for an evaluation of the impact of
vitiligo treatment. Therefore, the aim of this study was to
develop and validate a vitiligo-specific burden questionnaire
that we called the Vitiligo Impact Patient scale (VIPs).
RESULTS
Conceptual phase
The initial exploratory phase involved 25 patients who dis-
cussed their complaints and distresses related to vitiligo, and
input from two dermatologists, a patient support group, and
an expert in the design of questionnaires. During the course
of semistructured interviews and discussions, it became clear
that it would be relevant to include skin phototype as a
parameter in the questionnaire. After qualitative interviews,
the primary fields reported by patients were: (1) the feeling of
being discouraged by the condition, (2) the changes in
physical appearance, (3) discrimination at work, (4) the dif-
ficulty of initiating intimate relationships, (5) the general
feeling of unease, and (6) the financial burden related to the
disease. At this stage, 56 items were produced, then reor-
ganized and grouped according to their content, and finally
reduced to 35.
Development and validation phase
A total of 324 consecutive patients attending the clinic were
invited to participate. Of these, 301 agreed to participate. Of
these 301 individuals, 62% were females and 38% males.
The mean age of participants was 48.9  16.2 years (range,
1587 years). Individuals were classified as having fair skin
(I to III, n ¼ 235) or dark skin (IV to VI, n ¼ 66) phototype.
The majority of patients classified with dark skin were of
Middle Eastern, Caribbean, or Indian ethnicity. As the
responses to specific items varied significantly between fair
(I to III) and dark skin phototypes (IV to VI), we conducted all
analyses according to skin phototype.
First of all, exploratory factor analysis was conducted in all
participants to test the robustness of the global 35-item ques-
tionnaire. Three items were then deleted because of redun-
dancy and/or nondiscrimination. A further exploratory factor
analysis was then conducted on the remaining 32 items ac-
cording to skin phototype that identified a three-group model
as the most suitable for fair and dark skin phototypes.
Finally, the unidimensionality of VIPs-Fair Skin (FS) and
-Dark Skin (DS) was confirmed by the higher order factor
analysis. Hence, although the c2 values for both models were
statistically significant, which indicates that the models do
not perfectly predict all the covariances between the sub-
scales, the practical indices of fit (comparative fit index and
non-normed fit index) were acceptable for both models.
Indeed, the comparative fit index was 0.9083 and 0.9674,
respectively, for VIPs-DS and VIPs-FS (acceptable if greater
than 0.9) and the non-normed fit index was 0.9147 and
0.9621, respectively, for VIPs-DS and VIPs-FS (acceptable if
greater than 0.9).
For fair skin phototypes, the final version of VIPs-FS, which
was used in the psychometric analysis, consisted of 22 items.Standardized regression coefficients were all greater than 0.5
on their factor (Table 1). According to standardized regression
coefficients, each group of questions was assigned a dimen-
sion (each consisting of at least three questions): “Psycho-
logical effects on daily life” (9 questions), “Relationships and
Sexuality” (8 questions), and “Economic Constraints, Care &
Management of Disease” (5 questions). Cognitive debriefing
resulted in no major changes in the wording of the questions.
When conducting psychometric analysis, all dimensions
correlated well with the overall VIPs-FS score. Cronbach’s a
was 0.92 for the entire VIPs-FS, confirming an excellent in-
ternal coherence. Intradimensional coherences all demon-
strated excellent reliability (a > 0.8).
For dark skin phototypes, the final version of VIPs-DS,
which was used in the psychometric analysis, consisted of
26 items. Standardized regression coefficients were all
greater than 0.5 on their factor (Table 1). According to stan-
dardized regression coefficients, each group of questions was
assigned a dimension (each consisting of at least three
questions): “Psychological effects on daily life” (17 ques-
tions), “Economic Constraints, Care & Management of Dis-
ease” (5 questions) and “Relationships and Sexuality” (4
questions). Cognitive debriefing resulted in no major changes
in the wording of the questions. When conducting psycho-
metric analysis, all dimensions correlated well with the
overall VIPs-FS score. Cronbach’s a was 0.94 for the entire
VIPs-FS, confirming an excellent internal coherence. Intra-
dimensional coherences all demonstrated excellent reli-
ability (a > 0.80).
In total 29 items constituted the global VIPs questionnaire,
of which 19 were found in both dark and fair skin phototypes,
3 were specific to fair skin, and 7 to dark skin.
Results of the concurrent external validity are detailed in
Table 2. The correlation coefficients of the VIPs-FS and
VIPs-DS versus the Short-Form-12 (SF12), PVC Metra, Body
Image States Scale, and Daily Life Quality Index assessment
tools were highly correlated and confirmed the external
validity. Similarly, Bland and Altmann plots showed that
95% of the normalized differences between the VIPs-DS
(Figure 1) and VIP-FS (Figure 2) scores on the one hand
and the four other scores on the other hand were comprised
between 2SD.
Test-retest analysis. The test-retest reliability was obtained
in 118 evaluable patients, 80 and 38 respectively for VIPs-FS
and VIPs-DS, demonstrating very good reproducibility. The
Intra Class Correlation of each dimension was greater than
0.90 for each population and within each domain.
Translation and cross-cultural adaptation. The original
French versions of VIPs-FS and VIPs-DS have been translated
and have undergone linguistic and cultural validation in En-
glish (US).
Scoring. The VIPs can be reported as a total score (range,
0e110 for VIPs-FS and 0e130 for VIPs-DS). In these scores,
0 represents no effect and 110 maximal burden for fair-
skinned patients and 130 maximal burden for dark-skinned
patients. Finally, to allow a comparison between fair and
dark skin phototype, we propose to report scoring as a score
out of 100.www.jidonline.org 53
Table 1. Standardized regression coefficients from the final rotated factor pattern
Item Rotated factor pattern (standardized regression coefficients)
Dark skin phototypes Fair skin phototypes
Factor 1 Factor 2 Factor 3 Factor 1 Factor 2 Factor 3
1 I feel discouraged because of my vitiligo 0.57 0.17 0.20 0.68 0.27 0.22
2 I experience my vitiligo as a daily handicap 0.74 0.22 0.26 0.75 0.32 0.19
3 My vitiligo has repercussions on my physical appearance 0.52 0.07 0.38 0.66 0.27 0.04
4 Passing my vitiligo on to my children worries me, makes me anxious 0.50 0.22 0.20
5 I feel a sense of abandonment where medicine (my doctor) is concerned 0.09 0.07 0.70
6 I have learned to live with my vitiligo 0.59 0.01 0.15
7 My vitiligo has a negative impact on my libido (sexual desire) 0.43 0.20 0.54 0.17 0.72 0.01
8 The looks I get from people because of my vitiligo are hard to bear 0.73 0.046 0.37
9 My vitiligo is an obstacle (a barrier) to my sexuality 0.18 0.81 0.01
10 Questions about my vitiligo bother me, disturb me 0.72 0.21 0.27 0.35 0.66 0.27
11 I make sacrifices to afford my vitiligo treatments 0.01 0.69 0.05 0.08 0.25 0.77
12 My reflection in the mirror makes me anxious 0.57 0.30 0.18 0.80 0.30 0.22
13 In the evening, once I’ve applied all the creams, I feel depressed 0.15 0.46 0.55
15 I dip into my savings to treat my vitiligo 0.03 0.72 0.06 0.12 0.22 0.80
16 I have had to change my vacations, leisure activities because of my vitiligo 0.21 0.55 0.22
18 Managing my vitiligo on a daily basis is a burden 0.39 0.58 0.30 0.45 0.13 0.57
19 I tend to withdraw into myself because of my vitiligo 0.77 0.42 0.01 0.57 0.61 0.18
20 The progression of my vitiligo worries me (makes me anxious) 0.71 0.38 0.13 0.79 0.19 0.19
21 The looks in my loved ones’ eyes are difficult to bear 0.59 0.04 0.04 0.43 0.56 0.22
22 I sometimes feel like giving up 0.23 0.34 0.51
24 I often tell myself that my life would be very different without vitiligo 0.63 0.37 0.33 0.59 0.39 0.32
25 I am ashamed of the consequences of my vitiligo 0.79 0.22 0.04
27 I worry that my vitiligo will spread 0.58 0.40 0.20 0.67 0.02 0.14
28 I dread nice weather because of my vitiligo 0.63 0.26 0.19 0.77 0.20 0.23
29 I am not comfortable talking about my vitiligo with those around me 0.66 0.11 0.18 0.29 0.65 0.10
31 I feel that medicine has abandoned me 0.12 0.15 0.73
33 I dread first meetings because of my vitiligo 0.74 0.08 0.27 0.56 0.59 0.18
34 The looks I get from children because of my vitiligo are hurtful 0.55 0.07 0.07 0.27 0.59 0.30
35 Applying a treatment every day is a burden 0.05 0.51 0.39 0.25 0.02 0.57
Regression coefficients shown in bold typeface represent the individual items that were included in each dimension.
Table 2. Correlation coefficients for VIPs for dark and fair skin phototypes (three subscores for the three factors
and the total score) with PVC Metra, BISS, DLQI, and SF12 assessment tools
Dark skin phototypes Fair skin phototypes
Factor 1 Factor 2 Factor 3 Total score Factor 1 Factor 2 Factor 3 Total score
STRESS (PVC Metra) 0.41 0.26 0.25 0.41 0.45 0.48 0.32 0.49
P-value <0.01 0.03 0.04 <0.01 <0.01 <0.01 <0.01 <0.01
BISS 0.34 0.34 0.19 0.37 0.29 0.39 0.23 0.36
P-value <0.01 <0.01 0.13* <0.01 <0.01 <0.01 <0.01 <0.01
DLQI 0.77 0.62 0.57 0.84 0.76 0.74 0.60 0.82
P-value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
SF12_MCS 0.55 0.36 0.27 0.54 0.52 0.49 0.38 0.55
P-value <0.01 <0.01 0.03 <0.01 <0.01 <0.01 <0.01 <0.01
SF12_PCS 0.12 0.04 0.13 0.12 0.01 0.09 0.10 0.07
P-value 0.36* 0.72* 0.32* 0.33* 0.84* 0.19* 0.15* 0.33*
Abbreviations: BISS, Body Image States Scale; DLQI, Daily Life Quality Index; PVC Metra, Pre´vention Cardio-Vasculaire en MEdecine du TRAvail; MCS,
Mental Component Summary; PCS, Physical Component Summary; SF12, Short-Form-12; VIPs, Vitiligo Impact Patient scale.
*Nonsignificant.
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54DISCUSSION
To the best of our knowledge, VIPs is the first specific
assessment tool related to the burden of vitiligo. The notion of
“burden” is increasingly being reported in the medical field
in evaluating the care of chronic diseases, and moreJournal of Investigative Dermatology (2016), Volume 136specifically skin diseases (WHO, 2010). The notion of global
burden was introduced by the WHO. Besides, different
health authorities (NICE in the United Kingdom, HMO in the
United States, and HAS in France) take into account the in-
dividual burden of the disease to prioritize and determine the
Figure 1. Bland and Altman plots
between the total VIPs-DS score and
BISS, DLQI, SF12_PCS, and
SF12_MCS, respectively. BISS, Body
Image States Scale; DLQI, Daily Life
Quality Index; MCS, Mental
Component Summary; PCS, Physical
Component Summary; SF12, Short-
Form-12; VIPs-DS, Vitiligo Impact
Patient scale-Dark Skin.
Figure 2. Bland and Altman plots
between the total VIPs-FS score and
BISS, DLQI, SF12_PCS, and
SF12_MCS, respectively. BISS, Body
Image States Scale; DLQI, Daily
Life Quality Index; MCS, Mental
Component Summary; PCS, Physical
Component Summary; SF12, Short-
Form-12; VIPs-FS, Vitiligo Impact
Patient scale-Fair Skin.
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The Vitiligo Impact Patient Scalelevel of reimbursement of medical products. Individual
burden accounts for the broadest aspects of disease-related
disability, including psychological, physical, social, and
economic factors (Dufresne et al., 2013; Leidy et al., 1999;
Rannou et al., 2014; Seidenberg et al., 1994; Taieb et al.,2015), and may help to monitor specific disease before and
after therapy.
Based on this study, the preliminary validation of the VIPs
has been established. VIPs subscales were found to be psy-
chometrically robust, with excellent internal consistency andwww.jidonline.org 55
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56good item-scale, convergent, and construct validity. The VIPs
also correlated significantly with both components of the SF12
and with the Daily Life Quality Index, confirming its concur-
rent validity. The factor “Psychological” that was found in fair
and dark skin phototypes encompasses an array of distur-
bances in social life and includes almost half of the selected
items. The factor “Relationships and Sexuality” in VIPs-FS and
-DS assesses the impact of vitiligo on sexuality and shows that
psychological disturbances experienced by vitiligo patients
include irritability, anxiety, and depressive symptoms. Given
the potential severity of such symptoms, their assessment in
patients with vitiligo should not be neglected by dermatolo-
gists. Finally, the last factors “Psychological effects on daily
life” and “Economic Constraints, Care & Management of Dis-
ease” in both fair and dark skin phototypes assess actual con-
cerns that might significantly disturb a patient’s well-being:
treatment outcome in particular.
Vitiligo is often perceived as a cosmetic disorder, whereas
it has a major impact on patients’ QoL, and patients often
face discrimination and stigmatization from others (Kruger
and Schallreuter, 2015; Porter et al., 1987; Sukan and
Maner, 2007). Moreover, studies conducted in several
countries have shown that vitiligo has a major negative
impact on patients’ sexuality (Parsad et al., 2003a; Porter
et al., 1979; Sukan and Maner, 2007). Disappointingly, in a
survey conducted by the Vitiligo Society UK, a majority of
participants admit to obtaining information on vitiligo from
nonmedical sources (Talsania et al., 2010). Vitiligo has also
been associated with pessimistic emotions such as fear of
spreading of vitiliginous lesions, shame, insecurity, and
sadness (Nogueira et al., 2009). More generally, it is common
knowledge that a significant number of patients with vitiligo
feel stressed by their condition and experience shame,
depression, and anxiety leading to low self-esteem and social
isolation (Porter et al., 1978).
In a recent study, 55% of patients reported that emotional
stress has triggered their vitiligo (Vrijman et al., 2013).
Interestingly, in another study, psychological stress was found
to increase the level of neuroendocrine hormones with an
impact on the immune system (Al’Abadie et al., 1994).
Therefore, one plausible hypothesis is that this increase in
neuroendocrine hormones might be the initiating event in the
pathogenesis of vitiligo. In addition, previous studies have
shown that patients with decreased QoL at treatment initia-
tion have a lower response rate to a given treatment (Parsad
et al., 2003b). Despite this, there is limited research to
investigate the efficacy of psychological interventions in pa-
tients with vitiligo although some authors provide insights
into the interest possibility of cognitive behavior and other
psychological therapies in limiting disease progression
(Papadopoulos et al., 1999).
A few vitiligo-specific QoL instruments have been recently
developed (Gupta et al., 2014; Lilly et al., 2013; Senol et al.,
2013), but these are not completely satisfactory scales
because they do not address some aspects of the global
burden of the disease that remain unexplored. Our VIPs
questionnaire, when used in conjunction with vitiligo-
specific QoL measures, has the advantage of covering all
aspects of the burden of vitiligo in daily life. In addition, in a
recent review (Ezzedine et al., 2015) and in the latestJournal of Investigative Dermatology (2016), Volume 136Cochrane Skin Group review (Whitton et al., 2015), the need
for a specific burden questionnaire and psychological in-
terventions in vitiligo has been highlighted. The VIPs ques-
tionnaire may be a strategic tool for screening patients who
might benefit from psychological intervention. Moreover, the
VIPs questionnaire may also be an efficient method of
assessing the efficacy of these interventions. Another striking
characteristic of the VIPs questionnaire is its ability to weight
the burden of vitiligo according to skin phototype. In that
sense, the availability of a unique questionnaire with a
common denominator of 19 questions and 10 additional
items related to skin phototype will encourage the wide-
spread distribution of the questionnaire. We therefore suggest
the use of a single questionnaire whatever the phototype and
leave it up to the physician to use the skin phototype for the
interpretation of the scoring.
Given the increasing importance that regulatory author-
ities have placed on patient-reported outcomes (Committee
for Medicinal Products for Human Use, 2005; FDA, 2009)
and the fact that vitiligo is still considered as an orphan-
drug disease, the VIPs questionnaire aligns with the
patient-reported outcomes concept and provides supple-
mentary information by taking into account the burden of
vitiligo in adults in the broadest sense. It may also facilitate
negotiations between patient groups and health authorities
for the reimbursements of the cost of vitiligo treatments.
Indeed it is evident that in the field of dermatology there is
a pressing need for accurate tools to measure the burden of
skin disease. The VIPs questionnaire is an easy to use tool
for evaluating the vitiligo burden in adults and may also be
useful in the evaluation of the individual burden of vitiligo
before and after treatment.
Limitations associated with this study include that the cur-
rent cross-sectional analysis is limited by the classification of
vitiligo patients according to dermatologist-determined skin
phototype into two categories, rather than by individual
ethnicity. However, French health authorities do not allow
ethnic background data to be recorded, thus limiting any
possible correlation between the burden of vitiligo and
ethnicity. Larger confirmatory studies using the VIPs ques-
tionnaire are warranted to further explore some of the other
stages of Classical Test Theory, including confirmatory factorial
analysis and/or rash analysis. In addition, these studies should
ensure a larger population of individuals with skin phototypes
IVeVI, thus unearthing the potential intragroup differences
between individuals with these skin phototypes.
In conclusion, physicians should recognize the individual
burden of patients with vitiligo because treating only ac-
cording to disease severity may only be a partial acknowl-
edgment of patients’ suffering. The VIPs questionnaire may
increase awareness of the burden of vitiligo and therefore
ensure that vitiligo is no longer a “drug-orphan” and under-
funded disease.
METHODS
The VIPs questionnaire was developed using standardized QoL
questionnaire development and validation methodology (Seidenberg
et al., 1994). It consisted of three phases: conceptual, development,
and validation. A multidisciplinary working group of experts was
formed, including experts in questionnaire design and development
C Salzes et al.
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ment and care of patients with vitiligo (dermatologists), representa-
tives of patients’ association, and patient-reported outcomes experts.
Conceptual phase
The initial exploratory step involved the creation of a verbatim report
based on qualitative face-to-face interviews between dermatologist,
psychologist, and patients with vitiligo (n ¼ 25). These patients were
randomly selected from the list of adherents of the French support
group, “Association Franc¸aise du vitiligo.” On the basis of this report,
the working group created a list of items that were converted into
questions. A semistructured questionnaire was designed, containing
specific themes in a question-answer format, and “free speech” via
open-ended questions. A first assessment, simplifying the question-
naire and avoiding repetition, was conducted. This questionnaire
was then distributed to patients recruited from the vitiligo clinic of
the Department of Dermatology of Saint-Andre´ Hospital and patients
belonging to the patient support group “Association Franc¸aise du
Vitiligo,” between 1 February 2013 and 15 May 2013. All patients
attending the clinic for the first time who were given a confirmed
diagnosis of vitiligo were asked to participate in the study, and the
questionnaire was delivered once they had given their oral consent.
Patients were examined by a senior dermatologist. Eligible patients
were diagnosed with vitiligo of variable severity and were aged more
than 18 years; their mother tongue was French, so were, therefore,
able to read and understand the questionnaire in French.
Development phase
During the initial development phase, the working group made a
textual analysis of the preliminary questionnaire: the wording of
possible questions/answers was reviewed to group similar items,
remove indiscriminate questions (where greater than 90% of par-
ticipants, regardless of gender or age, responded similarly), and limit
redundancy. The choice of questions in the pilot questionnaire was
based on content and pertinence. The VIPs was produced in a
question/answer format. Responses were also determined by
consensus among the experts, using a 6-point Likert scale: “never”
(rated 0), “rarely” (1), “sometimes” (2), “often” (3), “very often” (4),
“constantly” (5). Another response “Not applicable” was included to
limit missing data and was rated 0. To avoid any confusion with QoL
impairment related to other symptoms of comorbidities, each
question included the word “vitiligo.”
An exploratory factor analysis was then performed to highlight the
underlying constructs and to determine the domain of each item. To
assess whether the hypothetical constructs pertaining to burden were
interrelated, an orthogonal (varimax) rotation was performed. Items
were considered for deletion if they loaded on two or more factors or
did not load on any factors. The questionnaire was then distributed
to patients recruited in the vitiligo clinic of the University Derma-
tology Department of Bordeaux, following the same eligibility
criteria as for the preliminary questionnaire.
To examine the unidimensionality of the VIPs, a higher order
factor confirmatory analysis was conducted on the VIP-FS and VIP-
DS subscale scores (PROC CALIS, SAS 9.4). Model fit was assessed
by multiple criteria: comparative fit index and non-normed fit index
for overall fit. The criteria for good model fit were defined as
comparative fit index greater than 0.90, and non-normed fit index
greater than 0.90 (Bentler, 1980).
Dimension scores were calculated by summing up individual
item scores and are reported as a score out of 100. A global score,
the sum of all individual item scores reported as a score out of 100,was expressed in percentage. A higher VIPs score reflects a higher
vitiligo burden.
Validation phase
All patients were asked to provide demographic and clinical infor-
mation (skin phototype, area of involvement, body surface area
affected) that were collected by the physician. In addition, all patients
were asked to complete four validated self-administered question-
naires: the Daily Life Quality Index questionnaire, the SF12 ques-
tionnaire, the Pre´vention Cardio-Vasculaire en MEdecine du TRAvail
(PCV Metra) questionnaire, Rosenberg’s Self-Esteem Scale.
The SF12,29 the short version of the SF-36, is a generic instrument
used to measure population health. A physical composite score and a
mental composite score can be calculated based on 12 questions.
There is no global SF12 score. TheDaily LifeQuality Index is a health-
related QoL scale specific for dermatological disorders scored in
percentages (0e100%) (Lewis and Finlay, 2004). Self-perceived stress
was evaluated with the PCV Metra, a self-administered stress ques-
tionnaire quoted 0e27 (the higher the score, the higher the stress)
(Consoli et al., 1997; Misery et al., 2008). The six-item Body Image
States Scale was used to provide a measure of individuals’ evaluative
and/or affective body image states (Cash et al., 2002).
Psychometric analysis—validation
Psychometric properties were evaluated by assessing the internal
consistency, the concurrent validity, and the discriminant validity of
VIPs.
For internal consistency reliability, the homogeneity of items in
each domain was evaluated using Cronbach’s a coefficient. This
coefficient including 0e1 corresponds to a degree of homogeneity.
A coefficient greater than 0.7 generally indicates good internal
reliability (Cronbach and Warrington, 1951).
Concurrent validity was determined by calculating the Spearman
coefficient (r) and Bland and Altmann plots between VIPs-FS/VIPs-
DS and the four other distributed questionnaires. Discriminant
(known-group) validity was analyzed according to age, gender, and
vitiligo severity and location, using the Wilcoxon and Mann-
Whitney test (as parameters were not distributed normally).
Data were analyzed using SAS software version 9.4 (SAS Institute,
Cary, NC) for Windows. A significance level of 0.05 was fixed for all
tests.
Test-retest analysis
To assess reproducibility, a test-retest analysis was conducted. Partici-
pants were retested after at least 2 weeks to allow for daily variations.
Translation, cross-cultural adaptation, and debriefing
cognitive
Although the original VIPs questionnaire was developed in French,
the following methodology (based on the Principles of Good Prac-
tice for the Translation and Cultural Adaptation Process for Patient-
Reported Outcomes Measures 21) was applied to generate
versions in other languages, and to account for cross-cultural vali-
dation. For each language, it was necessary to conduct linguistic and
cross-cultural validation following a rigorous process. This process
aims to refine the translation, taking into account the nuances of the
original version. Several changes can be implemented throughout
the validation process, without modifying the content. The aim is to
allow an improvement on the first idiomatic rendering. In addition,
the scales can be changed afterward based on cognitive debriefing,
to be consistent with the wording of the same question in the other
available languages.www.jidonline.org 57
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